KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Globus Medical (GMED) Shares Outstanding (Weighted Average) (2016 - 2025)

Globus Medical (GMED) has disclosed Shares Outstanding (Weighted Average) for 13 consecutive years, with $135.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) changed 0.38% year-over-year to $135.2 million, compared with a TTM value of $135.2 million through Dec 2025, changed 0.38%, and an annual FY2025 reading of $135.2 million, changed 0.38% over the prior year.
  • Shares Outstanding (Weighted Average) was $135.2 million for Q4 2025 at Globus Medical, roughly flat from $135.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $135.7 million in Q4 2024 and bottomed at $113.1 million in Q4 2023.
  • Average Shares Outstanding (Weighted Average) over 3 years is $128.0 million, with a median of $135.2 million recorded in 2025.
  • The sharpest move saw Shares Outstanding (Weighted Average) rose 20.02% in 2024, then dropped 0.38% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $113.1 million in 2023, then increased by 20.02% to $135.7 million in 2024, then fell by 0.38% to $135.2 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for GMED at $135.2 million in Q4 2025, $135.7 million in Q4 2024, and $113.1 million in Q4 2023.